USE OF IGF-1

摘要

2112358 9323071 PCTABS00028 The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus, the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.